Results 21 to 30 of about 8,965 (175)

Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. [PDF]

PLoS ONE, 2011
Reduction of proteinuria and blood pressure (BP) with blockers of the renin-angiotensin system (RAS) impairs the progression of chronic kidney disease (CKD).
Lene Boesby, Thomas Elung-Jensen, Tobias Wirenfeldt Klausen, Svend Strandgaard, Anne-Lise Kamper   +4 more
doaj   +1 more source

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy

Frontiers in Pharmacology, 2013
The mineralocorticoid receptor (MR) antagonists PF 03882845 and eplerenone were evaluated for renal protection against aldosterone mediated renal disease in uninephrectomized Sprague Dawley (SD) rats maintained on a high salt diet and receiving ...
Stephen eOrena, Stephen eOrena, Tristan eMaurer, Rena eEudy, Rena eEudy, Li eShe, Darla eDash, Paula eLoria, Mary Ellen eBanker, Vincent eBernardo, Meera eTugnait, Carlin eOkerberg, Jessie eQian, Carine M Boustany-Kari, Carine M Boustany-Kari   +14 more
doaj   +1 more source

Oral eplerenone for the management of chronic central serous chorioretinopathy [PDF]

International Journal of Ophthalmology, 2015
AIM: To examine eplerenone (Inspra, Pfizer), a mineralocorticoid receptor antagonist, as a treatment option for chronic central serous chorioretinopathy (CSCR).
Rishi P Singh, Jonathan E Sears, Rumneek Bedi, Andrew P Schachat, Justis P Ehlers, Peter K Kaiser   +5 more
doaj   +1 more source

Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy

Case Reports in Ophthalmology, 2015
Overactivation of mineralocorticoid receptor pathways has been implicated in the pathophysiology of central serous chorioretinopathy (CSCR). Recently, mineralocorticoid receptor antagonists such as eplerenone have demonstrated success in treating ...
Kapil G. Kapoor, Alan L. Wagner
doaj   +1 more source

Eplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Division

Frontiers in Endocrinology, 2020
Introduction: Mineralocorticoid receptor (MR) activation within adipose tissue, triggers inflammation and metabolic syndrome development. The pharmacological blockade of MR provides beneficial effects for adipose tissue. Our study evaluates the impact of
Andrea Vecchiola, Andrea Vecchiola, Cristóbal A. Fuentes, Isidora Solar, Carlos F. Lagos, Maria Cecilia Opazo, Maria Cecilia Opazo, Natalia Muñoz-Durango, Natalia Muñoz-Durango, Claudia A. Riedel, Claudia A. Riedel, Gareth I. Owen, Gareth I. Owen, Alexis M. Kalergis, Alexis M. Kalergis, Alexis M. Kalergis, Carlos E. Fardella, Carlos E. Fardella, Carlos E. Fardella   +18 more
doaj   +1 more source

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury

Frontiers in Pharmacology, 2021
The therapeutic indices (TIs) and efficacy of the non-steroidal mineralocorticoid receptor antagonist (MRA) KBP-5074 and steroidal MRA eplerenone were evaluated in a uninephrectomized Sprague Dawley rat model of aldosterone-mediated renal disease. In two
Frédéric Jaisser, Xiaojuan Tan, Shuangshuang Chi, Jinrong Liu, Ping Wang, Mark Bush, Vincent Benn, Y. Fred Yang, Jay Zhang   +8 more
doaj   +1 more source

Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats

Annals of Hepatology, 2012
Background. Eplerenone is a selective mineralocorticoid receptor (MR) antagonist, and its potential protective role in cardiovascular injury has been reported by several studies. However, whether and how this drug can ameliorate hepatic injury in rats is
Ashraf Taye, Ihab T. Abdel-Raheem
doaj   +1 more source

Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT

Efficacy and Mechanism Evaluation, 2021
Background: In chronic central serous chorioretinopathy, fluid accumulates in the subretinal space and causes permanent vision loss in ≈ 30% of patients. There is no definitive treatment.
Andrew Lotery, Sobha Sivaprasad, Abby O’Connell, Rosie A Harris, Lucy Culliford, Angela Cree, Savita Madhusudhan, Helen Griffiths, Lucy Ellis, Usha Chakravarthy, Tunde Peto, Chris A Rogers, Barnaby C Reeves   +12 more
doaj   +1 more source

Differential effects of eplerenone versus amlodipine on muscle metaboreflex function in hypertensive humans

The Journal of Clinical Hypertension, 2021
Numerous studies have demonstrated that sympathetic nervous system overactivation during exercise in hypertensive rodents and humans is due, in part, to an exaggerated reflex response known as the exercise pressor reflex.
Poghni A. Peri‐Okonny, Alejandro Velasco, Hamza Lodhi, Zhongyun Wang, Debbie Arbique, Beverley Adams‐Huet, Gary Iwamoto, Jere H. Mitchell, Masaki Mizuno, Scott Smith, Wanpen Vongpatanasin   +10 more
doaj   +1 more source

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. [PDF]

PLoS ONE, 2018
Excess mineralocorticoid receptor (MR) activation promotes target organ dysfunction, vascular injury and fibrosis. MR antagonists like eplerenone are used for treating heart failure, but their use is limited due to the compound class-inherent ...
Krister Bamberg, Ulrika Johansson, Karl Edman, Lena William-Olsson, Susanna Myhre, Anders Gunnarsson, Stefan Geschwindner, Anna Aagaard, Anna Björnson Granqvist, Frédéric Jaisser, Yufeng Huang, Kenneth L Granberg, Rasmus Jansson-Löfmark, Judith Hartleib-Geschwindner   +13 more
doaj   +1 more source